Category: Allergan Inc.Syndicate content

Report: Allergan CEO in line for $100M payout from Actavis deal

February 25, 2015 by Mark Hollmer

Allergan CEO David Pyott will get about $100 million in severance once his company’s merger with Actavis is completed, according to a news report.

David Pyott

Allergan (NYSE:AGN) Chairman and CEO David Pyott stands to earn $100 million once its multi-billion-dollar merger with Actavis (NYSE:ACT)  is consummated later this year.

CAH top suitor for JNJ's Cordis unit | The week in medtech M&A

February 25, 2015 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Cardinal Health top suitor for J&J's Cordis unit; 3M to buy Ivera Medical; Allergan name to live on post Actavis merger; Lumenis in talks to be acquired by Fosun for $480M; Uroplasty, Vision-Sciences set date for merger vote

Report: Cardinal Health top suitor for J&J's Cordis unit

February 23, 2015 by Brian Johnson

Report: J&J's selling its Cordis division

Allergan name to live on post Actavis merger

February 18, 2015 by Brian Johnson

Actavis CEO Brent Saunders tells CNBC that the company will adopt the Allergan name once the $66 billion merger closes.

Ackman supports Allergan's $66B sale to Actavis

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

2014 in review: Changes at the top for medical device companies

December 22, 2014 by MassDevice staff

There was a significant amount of turnover this year in the corner offices of medical device companies, including exits by some of medtech's biggest names.

2014 in review: Changes at the top for medical device companies

There was a revolving door on medtech's corner office this year, with more than 35 CEOs leaving their positions through planned transitions, retirement or termination, according to a MassDevice.com analysis.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Stryker may bid for Smith & Nephew following 6-month no-bid period | The week in medtech M&A

November 26, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew

Will Stryker bid on Smith & Nephew this week?

November 24, 2014 by Brad Perriello

Will Orange County's medtech scene lose its juice without Allergan?

November 20, 2014 by Brian Johnson

Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?

Will Orange County's medtech scene lose its juice without Allergan?

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy